A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

Provided herein are synthetic peptides and methods for treating cardiorespiratory diseases, particularly cardiopulmonary disorder (CPD) by use of the synthetic peptides. The present synthetic peptide has the amino acid sequence of X.sub.1EX.sub.2LRVANEVTLN (SEQ ID NO: 1), in which X.sub.1 is tyrosine (Y) or phenylalanine (F), and X.sub.2 is alanine (A) or cysteine (C). In preferred embodiments, an effective amount of the present synthetic peptide is administered to a subject suffering from CPD to ameliorate or alleviate symptoms associated therewith.

Provided herein are synthetic peptides and methods for treating cardiorespiratory diseases, particularly cardiopulmonary disorder (CPD) by use of the synthetic peptides. The present synthetic peptide has the amino acid sequence of X.sub.1EX.sub.2LRVANEVTLN (SEQ ID NO: 1), in which X.sub.1 is tyrosine (Y) or phenylalanine (F), and X.sub.2 is alanine (A) or cysteine (C). In preferred embodiments, an effective amount of the present synthetic peptide is administered to a subject suffering from CPD to ameliorate or alleviate symptoms associated therewith.

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 g/mL at pH 6.8.

The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the active pharmaceutical ingredient comprises a weakly basic active pharmaceutical ingredient having a solubility of not more than 100 g/mL at pH 6.8.

The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a pharmaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the blood.

The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a pharmaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the blood.